Roccuzzo Gabriele, Mastorino Luca, Gallo Giuseppe, Fava Paolo, Ribero Simone, Quaglino Pietro
Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
Clin Cosmet Investig Dermatol. 2022 Sep 13;15:1899-1907. doi: 10.2147/CCID.S273063. eCollection 2022.
Folliculotropic mycosis fungoides (FMF) is the most frequent variant of mycosis fungoides (MF), with clinical features which differ from the classic form. As for therapeutic options, the latest guidelines on MF agree on a stage-driven strategy, in consideration of clinical presentation, symptom burden and patient's comorbidities.
A search on MEDLINE, PubMed, Scopus and Cochrane Library was conducted to gather the latest evidence on FMF clinical management. Manuscripts published in the last five years (January 2017-April 2022) were included. Our single-center experience was also described.
A total of 15 articles were analyzed, with a total of 432 patients (disease stage from IA to IVA2). The most widely-used treatment was psoralen ultra-violet A (PUVA) in monotherapy or in association with other drugs. Oral retinoid-based therapy was also described as a therapeutic option alone or in combination. Other therapy reported were based on Brentuximab Vedotin, Mogamulizumab, Carmustine, topical steroids, tazarotene and excimer laser, interferon, nitrogen mustard, imiquimod, systemic chemotherapy, extracorporeal photopheresis and stem cell transplantation.
FMF is characterized by specific clinical-pathologic features. Advanced forms assume characteristics more similar to classic MF (infiltrated plaques and nodules), whilst early stages can present in a wide range of clinical forms (acneiform lesions, follicular-like keratoses, erythematous patches). As for therapeutic options, in absence of specific guidelines, a high number of treatments are described in clinical practice, with variable results. Phototherapy in all its forms, especially as PUVA, appears to have the greatest initial therapeutic success. Retinoids, although widely used, appear to be poorly effective in monotherapy, particularly acitretin. Combination treatment with phototherapy seems to be advisable. Ionizing treatments, such as radiotherapy and TSEBT, appear effective, at least in the short term. Overall, an integrated approach is mandatory for the inconstant course of the disease and its multidisciplinary nature.
毛囊性蕈样肉芽肿(FMF)是蕈样肉芽肿(MF)最常见的变异型,其临床特征与经典型不同。至于治疗方案,最新的MF指南基于临床表现、症状负担和患者合并症,一致认可采用分期驱动策略。
在MEDLINE、PubMed、Scopus和Cochrane图书馆进行检索,以收集FMF临床管理的最新证据。纳入过去五年(2017年1月至2022年4月)发表的手稿。还描述了我们的单中心经验。
共分析了15篇文章,涉及432例患者(疾病分期从IA到IVA2)。最广泛使用的治疗方法是补骨脂素紫外线A(PUVA)单药治疗或与其他药物联合使用。基于口服维甲酸的治疗也被描述为单独或联合的治疗选择。报告的其他治疗方法包括本妥昔单抗、莫加莫单抗、卡莫司汀、外用类固醇、他扎罗汀和准分子激光、干扰素、氮芥、咪喹莫特、全身化疗、体外光化学疗法和干细胞移植。
FMF具有特定的临床病理特征。晚期形式具有更类似于经典MF的特征(浸润性斑块和结节),而早期阶段可呈现多种临床形式(痤疮样皮损、毛囊样角化病、红斑性斑片)。至于治疗选择,在缺乏具体指南的情况下,临床实践中描述了大量治疗方法,结果各异。各种形式的光疗,尤其是PUVA,似乎最初的治疗成功率最高。维甲酸虽然广泛使用,但单药治疗效果似乎不佳,尤其是阿维A。光疗联合治疗似乎是可取的。电离治疗,如放射治疗和全身电子束照射,至少在短期内似乎有效。总体而言,鉴于该疾病病程不恒定及其多学科性质,综合治疗方法是必不可少的。